Eltrombopag for thrombocytopenia in patients with advanced solid tumors receiving gemcitabine-based chemotherapy: a randomized, placebo-controlled phase 2 study
In this phase 2 study, patients with solid tumors receiving gemcitabine monotherapy or gemcitabine plus cisplatin/carboplatin were randomized 2:1 to eltrombopag 100 mg (n = 52) or placebo (n = 23) for 5 days before and after chemotherapy was started. The primary endpoint was prechemotherapy (Day 1) platelet count across ≤6 cycles. Prechemotherapy platelet counts were numerically higher with eltrombopag than placebo. Frequencies of grades 3/4 thrombocytopenia were lower with eltrombopag in both the combination therapy (77 vs. 100%) and monotherapy (36 vs. 42%) groups. Proportionately fewer eltrombopag-treated patients had platelet counts <100 × 109/L at nadir. Among patients receiving combination chemotherapy, mean time to recovery from platelet nadir was 8 days with eltrombopag vs. 15 days with placebo. Eltrombopag-treated patients had fewer dose delays/reductions or missed doses due to thrombocytopenia in both the combination therapy (77 vs. 91%) and monotherapy (62 vs. 83%) groups. Adverse events and serious adverse events were less frequent with eltrombopag in both chemotherapy groups, with reduced rates of anemia, neutropenia, and thrombocytopenia in patients receiving combination chemotherapy. In conclusion, eltrombopag treatment shortened the time to recovery from platelet nadir in patients treated with gemcitabine-based chemotherapy and reduced dose delays/reductions due to thrombocytopenia.
KeywordsBlood platelets Cancer chemotherapy drugs Eltrombopag Thrombocytopenia Gemcitabine
Funding for this study (NCT01147809 available from https://clinicaltrials.gov/ct2/show/NCT01147809) was provided by GlaxoSmithKline; however, as of March 2, 2015, eltrombopag is an asset of Novartis AG. We thank Vassilios Aslanis, PharmD, of Novartis Pharmaceuticals Corporation, for his critical review of the manuscript and the pharmacology data. We also thank the patients and principal investigators and their institutions for their contributions to the study. All listed authors meet the criteria for authorship set forth by the International Committee for Medical Journal Editors. Editorial support (assembling tables and figures, collating author comments, copyediting, fact checking, and referencing) and graphic services were provided by Elizabeth Rosenberg, PhD, and Nancy E. Price, PhD, of AOI Communications, L.P., and were funded by Novartis Pharmaceuticals Corporation.
Compliance with ethical standards
Conflict of interest
EW, HS, BK, and SD have nothing to disclose. SB has provided consultancy for Blueprint Medicine, Novartis, and Pfizer. DK received honoraria from and provided consultancy for Incyte, Pfizer, and Pharmacyclics. PB held stock in and was an employee of GSK during the time of the study conduct and is now an employee of Novartis Pharma AG. SK was an employee of Novartis Pharmaceuticals Corporation and holds stock in Novartis. YMK was an employee of GlaxoSmithKline (GSK) during the time of study conduct and Novartis Pharmaceuticals Corporation, held GSK stock, and received travel accommodations and expenses from GSK. FF has received research funding from GSK.
- 5.Poplin E, Feng Y, Berlin J, Rothenberg ML, Hochster H, Mitchell E, et al. Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2009;27:3778–85.CrossRefPubMedPubMedCentralGoogle Scholar
- 6.Gemzar [package insert]. Indianapolis: Eli Lilly & Co; 2014.Google Scholar
- 7.Sederholm C, Hillerdal G, Lamberg K, Kölbeck K, Dufmats M, Westberg R, et al. Phase III trial of gemcitabine plus carboplatin versus single-agent gemcitabine in the treatment of locally advanced or metastatic non-small-cell lung cancer: the Swedish Lung Cancer Study Group. J Clin Oncol. 2005;23:8380–8.CrossRefPubMedGoogle Scholar
- 11.Paraplatin [package insert]. Princeton: Bristol-Myers Squibb; 2004.Google Scholar
- 13.Bussel JB, de Miguel PG, Despotovic JM, Grainger JD, Sevilla J, Blanchette VS, et al. Eltrombopag for the treatment of children with persistent and chronic immune thrombocytopenia (PETIT): a randomised, multicentre, placebo-controlled study. Lancet Haematol. 2015;2:e315–25.CrossRefPubMedGoogle Scholar
- 19.PROMACTA (eltrombopag) tablets for oral use [package insert]. East Hanover: Novartis; 2015.Google Scholar
- 21.Kellum A, Jagiello-Gruszfeld A, Bondarenko IN, Patwardhan R, Messam C, Mostafa Kamel Y, et al. A randomized, double-blind, placebo-controlled, dose ranging study to assess the efficacy and safety of eltrombopag in patients receiving carboplatin/paclitaxel for advanced solid tumors. Curr Med Res Opin. 2010;26:2339–46.CrossRefPubMedGoogle Scholar
- 24.Platzbecker U, Wong RS, Verma A, Abboud C, Araujo S, Chiou T, et al. Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial. Lancet Haematol. 2015;2:e417–26.CrossRefPubMedGoogle Scholar